-
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
Monday, January 22, 2024 - 9:15am | 882Read More...IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors. IN8bio...
-
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach
Monday, November 27, 2023 - 9:54am | 955Read More...Why Are Gamma-Delta T Cells Important In Fighting Cancer? Gamma-delta T cells belong to a unique group of immune cells that have qualities of both the innate and adaptive immune systems. They have a complex set of receptors that allow them to differentiate between healthy and cancerous cells. Their...
-
How IN8bio Is Working To Reach Its Goal Of "Cancer Zero" – Making Cancer A Thing of The Past
Thursday, November 2, 2023 - 8:17am | 1954Read More...IN8bio Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate residual tumors, and currently has two clinical programs focused on leukemia and on...




